- Conditions
- Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma
- Interventions
- WTX-330
- Drug
- Lead sponsor
- Werewolf Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 2 more
Location Directory
Clinical trials in Indianapolis, Indiana
This page shows live ClinicalTrials.gov search results for Indianapolis, Indiana, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
8611
Shown on this page
12
Current sort
Recently updated
Location scope
Indianapolis, IN
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 505–516 of 8,611 matching trials in Indianapolis, IN.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Adenovirus Infections
- Interventions
- cidofovir, Brincidofovir
- Drug
- Lead sponsor
- SymBio Pharmaceuticals
- Industry
- Eligibility
- 2 Months and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Duarte, California • Palo Alto, California + 25 more
- Conditions
- Alzheimer Disease
- Interventions
- Zunveyl®
- Drug
- Lead sponsor
- Alpha Cognition, Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 22
- States / cities
- Irvine, California • Orange, California • Aventura, Florida + 17 more
- Conditions
- Healthy Subjects
- Interventions
- Vagal Maneuvers, Multi-Electrode Array (MEA) Recording
- Other · Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Friedreich Ataxia, Cardiomyopathy
- Interventions
- Not listed
- Lead sponsor
- Lexeo Therapeutics
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 8
- States / cities
- La Jolla, California • Tampa, Florida • Indianapolis, Indiana + 5 more
- Conditions
- Gestational Diabetes, Pregnancy, High Risk, Overweight and Obesity
- Interventions
- Intensive glycemic targets, Standard glycemic targets
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 828 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Indianapolis, Indiana • Norman, Oklahoma + 2 more
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- zilucoplan (RA101495)
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 33
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Irvine, California + 29 more
- Conditions
- Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdoid Tumor of the Kidney, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Carcinoma, Recurrent WHO Grade 2 Glioma, Refractory Adrenal Gland Pheochromocytoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdoid Tumor of the Kidney, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Carcinoma, Refractory WHO Grade 2 Glioma
- Interventions
- Tipifarnib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 171
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- no intervention, database study
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Breast Cancer
- Interventions
- HCQ, Avelumab, Palbociclib
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 7
- States / cities
- Washington D.C., District of Columbia • Chicago, Illinois • Indianapolis, Indiana + 4 more
- Conditions
- Type 1 Diabetes, New Onset
- Interventions
- Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 9 Years to 20 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
- Interventions
- Renal Denervation (Symplicity Spyral™)
- Device
- Lead sponsor
- Medtronic Vascular
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,899 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 67 more